Jinsong Ni isn’t too worried about the pink slip he got from Allergan last week, perhaps because he has a PhD in chemistry and years of experience on the nonclinical side of the drugmaker’s R&D—the sort of early-stage investments it pledged to cut at its Irvine HQ amid a hostile takeover bid by Valeant last year...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to OCBJ.com archives
  • Book of Lists — the most comprehensive business resource in Orange County
  • NEW: Orange County 500 — influential business leaders you need to know
Yours for only $99